Carlsquare Corporate Finance
  • Deals
  • Services
    • Services
      • Corporate Finance
      • Growth Equity
      • Debt Advisory
      • IPO Strategie & Vorbereitung
      • Equity Research
    • Closed Deal

      Carlsquare hat Debtist beim Mehrheitsverkaufs an Norvestor beraten

  • Branchen
    • Branchen
      • Business Services
      • Consumer
      • Energy
      • Healthcare
      • Industrial Technology
      • Software
    • Deal News

      • Carlsquare hat die vitronet Holding GmbH beim Verkauf von Sandmann Infrastruktur GmbH an die New Energy Group beraten
  • Insights
    • Insights
      • Events
      • Insights
      • News
      • Newsletter
    • Insights

      • Europas Energiewende im Wettbewerb mit China und den USA
  • Weltweit
    • Weltweit
      • Dänemark
      • Deutschland
      • Frankreich
      • Kanada
      • Polen
      • Schweden
      • USA
      • Vereinigtes Königreich
    • Carlsquare Nordamerika

      Von Boston über San Francisco nach Vancouver: drei Standorte, eine globale Plattform

  • Über uns
    • Über uns
      • Wer wir sind
      • Karriere
      • Standorte
      • Team
      • In den Medien
      • Kontakt
    • Über uns

      Carlsquare gehört laut FINANCE zu den aktivsten Debt Advisors 2026

  • Kontakt
  • DE
    • INT

News

  • Alle
  • Company News
  • Deal News
  • Equity Research
  • Events
  • In den Medien
  • Insights
  • Märkte
Equity Research Biosergen: Candidozyma auris on the rise in Europe
17 Sep 2025
Equity Research Biosergen: Candidozyma auris on the rise in Europe
Equity Research Biosergen
Research update Biosergen: Ongoing development going according to plan
02 Sep 2025
Research update Biosergen: Ongoing development going according to plan
Equity Research Biosergen
Equity Research Biosergen: Stable quarter with exciting news around the corner
23 Mai 2025
Equity Research Biosergen: Stable quarter with exciting news around the corner
Equity Research Biosergen
Research update Biosergen: Continued success in India and cash injection
07 Mrz 2025
Research update Biosergen: Continued success in India and cash injection
Equity Research Biosergen
Carlsquare Equity Research interview with Biosergen
11 Feb 2025
Carlsquare Equity Research interview with Biosergen
Equity Research Biosergen
Research update Biosergen: Promising interim data as BSG005 saves lives
14 Nov 2024
Research update Biosergen: Promising interim data as BSG005 saves lives
Equity Research Biosergen
Carlsquare Equity Research interview with Biosergen
23 Sep 2024
Carlsquare Equity Research interview with Biosergen
Equity Research Biosergen
Research update Biosergen: First patient treated in phase Ib study a success
12 Sep 2024
Research update Biosergen: First patient treated in phase Ib study a success
Equity Research Biosergen
Research update Biosergen: Taking the next clinical step
05 Jul 2024
Research update Biosergen: Taking the next clinical step
Equity Research Biosergen
Equity Research Biosergen: Study permission received, BSG005 ready for testing in patients
11 Jun 2024
Equity Research Biosergen: Study permission received, BSG005 ready for testing in patients
Equity Research Biosergen
Research update Biosergen: Rights issue to fund crucial step for lead project
13 Mrz 2024
Research update Biosergen: Rights issue to fund crucial step for lead project
Equity Research Biosergen
Carlsquare Equity Research interview with Biosergen
07 Mrz 2024
Carlsquare Equity Research interview with Biosergen
Equity Research Biosergen
Equity research Biosergen: Rights issue to fund the next clinical step
02 Feb 2024
Equity research Biosergen: Rights issue to fund the next clinical step
Equity Research Biosergen
Research Update Biosergen: Licensing deal with Alkem and CTA submission
16 Jan 2024
Research Update Biosergen: Licensing deal with Alkem and CTA submission
Equity Research Biosergen
Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline
16 Aug 2023
Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline
Equity Research Biosergen
Equity research Biosergen: Plans for speedy development of lead candidate
29 Mrz 2023
Equity research Biosergen: Plans for speedy development of lead candidate
Equity Research Biosergen
Initiation of coverage, Biosergen: Make antifungals great again
20 Mrz 2023
Initiation of coverage, Biosergen: Make antifungals great again
Equity Research Biosergen
Carlsquare Corporate Finance Closing Deals.
  • DEALS
    • Business Services
    • Consumer
    • Energy
    • Healthcare
    • Industrial Technology
    • Software
  • SERVICES
    • Corporate Finance
    • Debt Advisory
    • Equity Research
    • Growth Equity
    • IPO Strategie & Vorbereitung
  • BRANCHEN
    • Business Services
    • Consumer
    • Energy
    • Healthcare
    • Industrial Technology
    • Software
  • WELTWEIT
    • Dänemark
    • Deutschland
    • Frankreich
    • Kanada
    • Polen
    • Schweden
    • USA
    • Vereinigtes Königreich
  • ÜBER UNS
    • Wer wir sind
    • Karriere
      • Life at Carlsquare
      • Offene Stellen
      • Studierende
      • Young Professionals
      • Experienced Professionals
    • Team
    • Standorte
    • Kontakt
  • INSIGHTS
    • Events
    • Insights
    • In den Medien
    • News
    • Newsletter
GLOBALSCOPE
Subscribe to Newsletter
© 2026 Carlsquare GmbH
  • Datenschutz & Haftungsausschluss
  • Impressum